Synexus Polska Sp. z o.o.

At Synexus Polska Sp. z o.o. in Warsaw, research in musculoskeletal diseases focuses on post-menopausal osteoporosis and related bone loss conditions. These studies are designed to compare treatment options and assess whether new therapies can help protect bone strength and reduce the impact of osteoporosis.

• Post-menopausal osteoporosis
• Evaluating treatment effectiveness for stronger bone health
• Comparing investigational therapy with an established option

This area reflects a broader interest in improving care for patients with conditions that weaken the skeleton and increase fracture risk.

Clinical trial activity in nervous system diseases includes studies of chronic peripheral neuropathic pain, especially pain linked to postherpetic neuralgia or peripheral nerve injury. The goal is to test whether new pain treatments can reduce symptoms more effectively than placebo and improve daily comfort for patients living with persistent nerve pain.

• Moderate to severe chronic peripheral neuropathic pain
• Postherpetic neuralgia
• Peripheral nerve injury-related pain

These trials aim to expand options for people whose pain is difficult to control with standard care.

Work in nutritional and metabolic diseases centers on Non Alcoholic Steatohepatitis and Metabolic Dysfunction-Associated Steatohepatitis, including cases with fibrosis. The research is designed to evaluate whether a new therapy can support liver health, improve disease resolution, and slow progression of liver damage.

• Non Alcoholic Steatohepatitis
• Metabolic Dysfunction-Associated Steatohepatitis
• Fibrosis

These studies are important for patients with metabolic liver disease, where effective treatment options remain limited.

Research in skin and connective tissue diseases includes studies of moderate to severe atopic dermatitis. The trials are aimed at determining whether a new treatment can better control inflammation, improve skin symptoms, and help patients achieve meaningful relief compared with placebo.

• Moderate to severe atopic dermatitis
• Assessing control of inflammatory skin symptoms
• Testing a potential new therapy for eczema-related disease burden

This reflects a strong focus on improving quality of life for people affected by long-lasting, itchy, and visibly distressing skin disease.